We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cyclerion

News List

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership firstwordpharma
July 09, 2021
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.
Cyclerion Announces Sickle Cell Disease Study Results americanpharmaceuticalreview
October 22, 2020
Cyclerion Therapeutics announced top-line results from its STRONG-SCD study of olinciguat, an investigational, orally-administered, once daily, vascular sGC stimulator for the potential treatment of sickle cell disease (SCD).
Cyclerion Announces Positive Data from CNS Translational Study in Healthy Elderly Subjects americanpharmaceuticalreview
October 21, 2020
Cyclerion Therapeutics announced results from its Phase 1 translational pharmacology study of IW-6463, the first soluble guanylate cyclase (sGC) stimulator in clinical development for CNS disorders.